NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver cirrhosis
Disease control OngoingThis study tests an experimental drug called efinopegdutide in 80 adults with liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can lower liver fat, inflammation, and scarring compared …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
Could a blood pressure pill protect your liver from cancer?
Disease control OngoingThis study tests whether lisinopril, a widely used blood pressure medication, can slow the progression of non-alcoholic fatty liver disease (NAFLD) and lower the risk of liver cancer. About 45 adults with advanced liver scarring (fibrosis) will take lisinopril for a period, and r…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Hidden liver risk in type 1 diabetes revealed by new study
Knowledge-focused OngoingThis study looks at how often people with type 1 diabetes have nonalcoholic fatty liver disease (NAFLD) and serious liver scarring. Researchers used a painless ultrasound-like test and blood scores to check 533 adults at a diabetes clinic. The goal is to find high-risk patients w…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Joslin Diabetes Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:39 UTC